BR112016029571A2 - compostos, composição farmacêutica e uso dos mesmos no tratamento de distúrbios neurodegenerativos - Google Patents
compostos, composição farmacêutica e uso dos mesmos no tratamento de distúrbios neurodegenerativosInfo
- Publication number
- BR112016029571A2 BR112016029571A2 BR112016029571A BR112016029571A BR112016029571A2 BR 112016029571 A2 BR112016029571 A2 BR 112016029571A2 BR 112016029571 A BR112016029571 A BR 112016029571A BR 112016029571 A BR112016029571 A BR 112016029571A BR 112016029571 A2 BR112016029571 A2 BR 112016029571A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- treatment
- pharmaceutical composition
- neurodegenerative disorders
- solvates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
a presente invenção é direcionada a novos compostos de fórmula (i), sais farmaceuticamente aceitáveis ou solvatos dos mesmos, e o uso deles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14305919 | 2014-06-16 | ||
PCT/EP2015/063370 WO2015193255A1 (en) | 2014-06-16 | 2015-06-15 | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016029571A2 true BR112016029571A2 (pt) | 2017-08-22 |
Family
ID=50982878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016029571A BR112016029571A2 (pt) | 2014-06-16 | 2015-06-15 | compostos, composição farmacêutica e uso dos mesmos no tratamento de distúrbios neurodegenerativos |
Country Status (29)
Country | Link |
---|---|
US (3) | US10179761B2 (pt) |
EP (1) | EP3154934B1 (pt) |
JP (1) | JP6704355B2 (pt) |
KR (1) | KR20170041662A (pt) |
CN (1) | CN106795100B (pt) |
AU (1) | AU2015276256B2 (pt) |
BR (1) | BR112016029571A2 (pt) |
CA (1) | CA2951438C (pt) |
CL (1) | CL2016003230A1 (pt) |
CO (1) | CO2017000211A2 (pt) |
CR (1) | CR20160581A (pt) |
DO (1) | DOP2016000325A (pt) |
EA (1) | EA031123B1 (pt) |
EC (1) | ECSP16094286A (pt) |
ES (1) | ES2880313T3 (pt) |
GT (1) | GT201600255A (pt) |
IL (1) | IL249440B (pt) |
MA (1) | MA39533B1 (pt) |
MX (1) | MX2016016769A (pt) |
MY (1) | MY183757A (pt) |
PE (2) | PE20170518A1 (pt) |
PH (1) | PH12016502480A1 (pt) |
PL (1) | PL3154934T3 (pt) |
PT (1) | PT3154934T (pt) |
SG (1) | SG11201610478YA (pt) |
TN (1) | TN2016000550A1 (pt) |
UA (1) | UA123041C2 (pt) |
WO (1) | WO2015193255A1 (pt) |
ZA (1) | ZA201608558B (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI744300B (zh) * | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
WO2024033399A1 (en) | 2022-08-10 | 2024-02-15 | Institut National de la Santé et de la Recherche Médicale | Sigmar1 ligand for the treatment of pancreatic cancer |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2241498A (en) * | 1940-11-25 | 1941-05-13 | Champ Items Inc | Method of manufacturing oil shields for internal combustion engines |
US2441498A (en) * | 1943-07-15 | 1948-05-11 | Astra Apotekarnes Kem Fab | Alkyl glycinanilides |
GB1307250A (en) | 1970-06-16 | 1973-02-14 | May & Baker Ltd | Benzene derivatives |
DE2438288A1 (de) * | 1974-08-09 | 1976-02-19 | Knoll Ag | Neue antiarrhythmika |
US4448776A (en) | 1981-02-12 | 1984-05-15 | Karl Bucher | Method of using certain substituted aliphatic secondary amines or their salts for easing breathing |
JPH02138162A (ja) * | 1988-11-19 | 1990-05-28 | Mitsubishi Kasei Corp | N−フェニルアルキル置換−β−アミノ酸アミド誘導体 |
WO1992022279A2 (en) * | 1991-06-06 | 1992-12-23 | G.D. Searle & Co. | N-[arylethyl]-n-alkyl-2-(1-pyrrolidinyl)ethylamine derivatives for cns disorders |
JPH07188139A (ja) * | 1993-12-24 | 1995-07-25 | Kirin Brewery Co Ltd | アミド化合物 |
FR2729146A1 (fr) * | 1995-01-06 | 1996-07-12 | Smithkline Beecham Lab | Nouveaux derives d'amine, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques |
EP1615698B1 (en) * | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
BRPI0519040A2 (pt) | 2004-12-15 | 2009-01-13 | Bayer Schering Pharma Ag | tiazolidinonas metassubstituÍdas, sua produÇço e uso como medicamentos |
CA2709186A1 (en) * | 2007-12-19 | 2009-06-25 | Wyeth Llc | 4-imidazolidinones as kv1.5 potassium channel inhibitors |
CA2839956A1 (en) * | 2011-06-20 | 2012-12-27 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
US20130274233A1 (en) * | 2012-04-03 | 2013-10-17 | President And Fellow Of Harvard College | Modulators of hedgehog signaling pathway |
-
2015
- 2015-06-15 US US15/317,742 patent/US10179761B2/en active Active
- 2015-06-15 MX MX2016016769A patent/MX2016016769A/es unknown
- 2015-06-15 MA MA39533A patent/MA39533B1/fr unknown
- 2015-06-15 MY MYPI2016002188A patent/MY183757A/en unknown
- 2015-06-15 CR CR20160581A patent/CR20160581A/es unknown
- 2015-06-15 PT PT157304619T patent/PT3154934T/pt unknown
- 2015-06-15 PE PE2016002712A patent/PE20170518A1/es not_active Application Discontinuation
- 2015-06-15 JP JP2016573483A patent/JP6704355B2/ja active Active
- 2015-06-15 AU AU2015276256A patent/AU2015276256B2/en not_active Ceased
- 2015-06-15 SG SG11201610478YA patent/SG11201610478YA/en unknown
- 2015-06-15 EA EA201790020A patent/EA031123B1/ru not_active IP Right Cessation
- 2015-06-15 WO PCT/EP2015/063370 patent/WO2015193255A1/en active Application Filing
- 2015-06-15 BR BR112016029571A patent/BR112016029571A2/pt not_active Application Discontinuation
- 2015-06-15 ES ES15730461T patent/ES2880313T3/es active Active
- 2015-06-15 CN CN201580032317.6A patent/CN106795100B/zh active Active
- 2015-06-15 KR KR1020167036029A patent/KR20170041662A/ko not_active Application Discontinuation
- 2015-06-15 EP EP15730461.9A patent/EP3154934B1/en active Active
- 2015-06-15 PL PL15730461T patent/PL3154934T3/pl unknown
- 2015-06-15 TN TN2016000550A patent/TN2016000550A1/en unknown
- 2015-06-15 UA UAA201700333A patent/UA123041C2/uk unknown
- 2015-06-15 CA CA2951438A patent/CA2951438C/en active Active
-
2016
- 2016-12-07 IL IL249440A patent/IL249440B/en active IP Right Grant
- 2016-12-08 GT GT201600255A patent/GT201600255A/es unknown
- 2016-12-12 ZA ZA2016/08558A patent/ZA201608558B/en unknown
- 2016-12-12 PH PH12016502480A patent/PH12016502480A1/en unknown
- 2016-12-13 DO DO2016000325A patent/DOP2016000325A/es unknown
- 2016-12-14 EC ECIEPI201694286A patent/ECSP16094286A/es unknown
- 2016-12-15 CL CL2016003230A patent/CL2016003230A1/es unknown
-
2017
- 2017-01-10 CO CONC2017/0000211A patent/CO2017000211A2/es unknown
-
2018
- 2018-03-13 PE PE2018000386A patent/PE20181053A1/es unknown
- 2018-11-30 US US16/205,637 patent/US10844008B2/en active Active
-
2020
- 2020-10-22 US US17/077,530 patent/US20210040034A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
BR112017013440A2 (pt) | compostos de isoquinolina para o tratamento de hiv | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
BR112016015365A8 (pt) | composto, composição farmacêutica e uso de um composto | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
BR112017013491A2 (pt) | compostos de pirimidina fundida para o tratamento de hiv | |
CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
EA201790785A1 (ru) | Производные тетрагидроизохинолина | |
MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
AR103680A1 (es) | Inhibidores selectivos de bace1 | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
BR112017007414A2 (pt) | combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
CL2016002839A1 (es) | Derivados de carboxamida | |
BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях | |
CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
BR112019008415A2 (pt) | composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |